View Older Stories View More Recent Stories

Feb 22, 2025 10:17PM ROSEN, A LEADING FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 22, 2025 08:16AM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Feb 22, 2025 04:00AM What's the current state of China's GLP-1 market?
Feb 21, 2025 07:28PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 21, 2025 04:00PM MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 20, 2025 11:25AM MRK INVESTOR DEADLINE: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 19, 2025 03:44PM ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 18, 2025 06:51PM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Feb 18, 2025 04:25PM IVF stocks on watch as President Trump signs an executive order to expand access
Feb 18, 2025 11:40AM Merck And Plaintiff Suing Over Alleged Gardasil Vaccine Injuries Agree To Delay Trial Until September 2025 With New Jury - Reuters
Feb 18, 2025 06:45AM Merck (MRK) Reports WELIREG Received First European Commission Approval for Two Indications
Feb 17, 2025 02:04PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 16, 2025 04:00PM MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 15, 2025 09:25PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 15, 2025 09:33AM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Feb 14, 2025 02:30PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 12, 2025 07:09AM Merck (MRK) PT Lowered to $115 at Guggenheim
Feb 12, 2025 07:02AM Neuphoria (NEUP) to Receive $15M Milestone Payment from Merck
Feb 11, 2025 05:50AM Merck (MRK) PT Lowered to $95 at Bernstein SocGen Group
Feb 10, 2025 05:29AM TD Cowen Downgrades Merck (MRK) to Hold
Feb 6, 2025 06:45AM Merck (MRK) Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin
Feb 5, 2025 10:22AM Merck (MRK) PT Lowered to $96 at BMO Capital as 'Gardasil Cut Lowers Confidence'
Feb 5, 2025 06:35AM Merck (MRK) PT Lowered to $129 at Goldman Sachs
Feb 4, 2025 06:31AM Merck (MRK) Misses Q4 EPS by 9c; misses on outlook
Feb 3, 2025 10:37AM Merck (MRK) call put ratio 3.1 calls to 1 put with a focus on February 7 weekly 100 calls
Feb 3, 2025 05:04AM Merck (MRK) call put ratio 2.3 calls to 1 put into quarter results
Jan 31, 2025 10:37AM Merck (MRK) call put ratio 3.1 calls to 1 put with a focus on January 2027 100 calls
Jan 31, 2025 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for CAPVAXIVE
Jan 31, 2025 05:16AM Merck (MRK) February 7 weekly 99 straddle priced into quarter results
Jan 30, 2025 06:45AM Merck (MRK) to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR Early and Move to Final Analysis
Jan 28, 2025 01:28PM Merck (MRK) Declares $0.81 Quarterly Dividend; 3.3% Yield
Jan 28, 2025 01:28PM Merck (MRK) Announces $10B Share Buyback
Jan 24, 2025 06:45AM Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA Plus LENVIMA in Combination with Chemotherapy
Jan 17, 2025 07:11AM Merck (MRK) PT Lowered to $122 at Guggenheim
Jan 13, 2025 11:14AM Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
Jan 8, 2025 06:48AM Merck's (MRK) GARDASIL Receives Expanded Approval for Males in China
Jan 7, 2025 11:00AM TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
Jan 2, 2025 12:39PM TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
Dec 20, 2024 06:45AM Merck (MRK) Closes Exclusive Global License Agreement for LM-299
Dec 20, 2024 04:09AM BMO Capital Downgrades Merck (MRK) to Market Perform
Dec 19, 2024 07:34AM Merck (MRK) 'Buys' GLP-1 (HS-10535) From China; Bernstein Reiterates Market Perform Rating
Dec 19, 2024 06:45AM Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir
Dec 18, 2024 08:20AM BMO Capital on Merck's obesity deal (MRK): 'transaction likely viewed as positive, but Merck would have been better served going after later-stage development'
Dec 18, 2024 07:51AM Viking Therapeutics (VKTX) weakness tied to Merck's (MRK) Deal for GLP-1 Receptor Agonist
Dec 18, 2024 06:45AM Merck (MRK) Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
Dec 17, 2024 06:49AM Bernstein SocGen Group Reiterates Market Perform Rating on Merck (MRK)
Dec 17, 2024 06:46AM Merck (MRK) Announces FDA Acceptance of BLA for Clesrovimab
Dec 16, 2024 04:30PM Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab
Dec 16, 2024 06:45AM Merck's (MRK) KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment
Dec 13, 2024 07:06AM Merck (MRK) Receives Positive EU CHMP Opinion for WELIREG
View More Recent Stories View Older Stories